G
Genetic Archaeology
GENETIC ARCHAEOLOGY // PROFILE

MLH1

MutL Homolog 1

CHR 3
3p22.2

Overview

The MLH1 gene serves as the molecular proofreader of rapidly dividing tissues, especially the colonic lining and endometrium. Partnering with PMS2 and MSH2 in the DNA mismatch repair (MMR) complex, MLH1 detects and repairs tiny base mismatches left behind during DNA replication.

Germline loss-of-function variants in MLH1 represent the single leading cause of Lynch syndrome—making proactive medical surveillance highly effective, as covered in our Lynch syndrome prevention guide.

📍 Position
3p22.2 (Chromosome 3)
🏷️ Category
Tumor Suppressor & DNA Repair
🧪 Function
DNA Mismatch Repair (MMR)
📊 Influence
Lynch syndrome & colon screening

Function of MLH1

When one inherited MLH1 copy is faulty, remaining healthy MMR protein still protects cells—until a random somatic hit disables the second copy inside a mucosal cell, triggering rapid microsatellite instability (MSI-H).

Key Aspects:

🔎 Early Colonoscopy Saves Lives

Because precancerous polyps are detected and removed painlessly via colonoscopy every 1–2 years starting in young adulthood, early screening slashes mortality sharply.

🧪 Diagnostic vs. DTC Arrays

Consumer SNP arrays cover almost none of the hundreds of private MLH1 mutations; medical diagnosis requires full clinical gene sequencing and deletion testing.

💡 Clear Guidance: A pathogenic MLH1 variant does not mean certainty of cancer—it signals high actionability where NCCN and ESMO guidelines enable individualized colonoscopic and gynecologic surveillance.

🧬 Genetic Variants (SNPs)

Clinical MLH1 testing distinguishes common promoter polymorphisms from rare high-penetrance Lynch mutations:

rs1800734
3:36993455
Reference

G
/
Promoter

A
MLH1 -93G>A
Common benign-to-low-risk promoter variant studied alongside somatic MLH1 hypermethylation in sporadic colon polyps (not classic Lynch syndrome).
A allele frequency:
~22% (Europe)
rs63750217
3:37048955
Normal

G
/
Pathogenic

A
c.2041G>A (p.Ala681Thr)
Rare ClinVar-pathogenic missense substitution that disrupts MLH1 protein stability and triggers hereditary Lynch syndrome cancer predisposition.
Population status:
Very rare (<0.01%)

Practical Significance

✅ Strategies & Guidance

  • Review Three-Generation Family History: Early-onset colon or uterine cancer (<50) warrants referral to a board-certified genetic counselor.
  • Regular Screening Colonoscopies: Confirmed MLH1 carriers follow accelerated colonoscopy schedules starting around age 20–25.
  • Cascade Family Testing: First-degree relatives (siblings, children, parents) can be tested definitively for a known familial variant (50% transmission probability).

⚠️ Clinical Notes & Risks

  • Colorectal & Endometrial Risk: Elevated lifetime cancer risk across GI tract, uterus, ovaries, and stomach when unmonitored.
  • False Reassurance from Home Kits: Normal 23andMe/Ancestry results do not rule out Lynch syndrome.
  • Tumor MMR / MSI Testing: Pathology teams routinely screen colon and uterine tumors for MLH1 protein loss.
🩺 Medical Disclaimer: Genetic test results for MLH1 (MutL Homolog 1) should always be interpreted alongside laboratory biomarkers, medications, and qualified medical or genetic counseling.

📚 Data Sources

  • OMIM: #120436 (MutL Homolog 1) & #120435 (Lynch Syndrome 2)
  • dbSNP & ClinVar: rs1800734, InSiGHT MMR Variant Database
  • NCCN Clinical Guidelines: Genetic/Familial High-Risk Assessment (Colorectal / Lynch Syndrome)
  • ESMO Clinical Practice Guidelines: Hereditary Gastrointestinal Cancers

Last Update: November 2026

Related Research Guides for MLH1

Related Genes in Tumor Suppressor